(1) As used in this section:

(a) "Health care provider" means the same as that term is defined in Section 78B-3-403.

(b) "Human cells, tissues, or cellular or tissue-based products" has the same meaning as in 21 C.F.R. Sec. 1271.3 as it exists on May 1, 2024.

(c) (i) "Stem cell therapy" means a treatment involving the use of afterbirth placental perinatal stem cells or human cells, tissues, or cellular or tissue-based products.

(ii) "Stem cell therapy" does not include treatment or research using human cells or tissues that were derived from a fetus or embryo after an abortion.

(2) A health care provider whose scope of practice includes the use of stem cell therapy Ŝ→ [~~and~~] ←Ŝ may perform a stem cell therapy that is not approved by the United States Food and Drug Administration, if the health care provider provides the patient with the following written notice before performing the therapy:

"THIS NOTICE MUST BE PROVIDED TO YOU UNDER UTAH LAW. This health care practitioner performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing a stem cell therapy."

(3) (a) The written notice described in Subsection (2) shall be:

(i) on paper that is at least eight and one-half inches by eleven inches; and

(ii) written in no less than forty point type.

(b) The health care provider shall prominently display the written notice in the entrance and in an area visible to patients in the health care provider's office.

(4) (a) A health care provider who is required to provide written notice under Subsection (2) shall obtain a signed consent form before performing the therapy.

(b) The consent form shall:

(i) be signed by the patient, or, if the patient is legally not competent, the patient's representative; and

(ii) state, in language the patient could reasonably be expected to understand:

(A) the nature and character of the proposed treatment, including the treatment's United States Food and Drug Administration approval status;

(B) the anticipated results of the proposed treatment;